UNSPSC 51282128: Faropenem daloxate

This classification denotes a beta-lactam antibiotic with the molecular formula C17H19NO8S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5OK523O4FU, chemically known as 4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 6-((1r)-1-hydroxyethyl)-7-oxo-3-((2r)-tetrahydro-2-furanyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, (5r,6s), but more generally known as faropenem daloxate, which bears US NIH Compound Identifier 6918218.

European Medicines Agency schedules faropenem daloxate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07512MIG. Most nations, for tariff purposes, schedule faropenem daloxate under HS 29419000. SMILES: CC1C(OC(=O)O1)COC(=O)C2=C(S[C@H]3N2C(=O)[C@@H]3[C@@H](C)O)[C@H]4CCCO4.

UNSPSC 51282128 Faropenem daloxate is a Commodity code for a specific pharmaceutical product; however, the recent state and local opportunities tagged under this code do not reflect procurement of faropenem daloxate itself, but rather unrelated pharmaceutical products and medical supplies including antibiotics, naloxone, and drug deactivation systems. The code sees minimal relevant activity — the opportunities posted show mismatch between the nominal code definition and what state and local buyers are actually purchasing under this classification.

The Illinois Department of Public Health awarded a piggyback pharmaceutical contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026, for Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets totaling $2,999,999.11 over the life of the contract with a 12-month initial term and two renewal options. Seminole County, Florida posted an IFB on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, though the response deadline shown in the record (July 26, 2023) reflects a data error. These solicitations indicate that state health departments and county public health agencies drive pharmaceutical procurement under this code tier, but the absence of faropenem daloxate in recent activity and the frequent mismatch between code assignment and product scope suggest this specific commodity code does not reflect current state and local buying patterns.